Estrogenic effects of the ethyl-acetate extract of the stem bark of Erythrina lysistemon Hutch (Fabaceae)

Phytomedicine

Volumn 14, Issue 2-3, 2007, Pages 222-226

  Tanee, F S F ^a   Njamen, D ^a   Magne Nde C B ^a   Wanji, J ^a   Zierau, O ^b   Fomum, Z T ^a   Vollmer, G ^b  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Erythrina lysistemon; Estrogenicity; Ethyl acetate extract; Uterotrophy

Indexed keywords

ALKALINE PHOSPHATASE; ERYTHRINA EXTRACT; ERYTHRINA LYSISTEMON EXTRACT; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BARK; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOMETRIUM CARCINOMA; ENZYME ACTIVITY; EPITHELIUM CELL; ERYTHRINA; ERYTHRINA LYSISTEMON; ESTROGEN ACTIVITY; FEMALE; GENITAL SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OVARIECTOMY; PLANT STEM; PRIORITY JOURNAL; RAT; TREATMENT DURATION; UTERUS; VAGINA;

ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHRINA; FEMALE; OVARIECTOMY; PHYTOESTROGENS; PHYTOTHERAPY; PLANT BARK; PLANT EXTRACTS; RATS; RATS, WISTAR; UTERUS; VAGINA;

ERYTHRINA LYSISTEMON; FABACEAE; RATTUS;

EID: 33846362630     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2006.01.012     Document Type: Article

References (16)

1. Bisby F.A., Buckingham J., and Harborne J.B. Phytochemical Dictionary of the Leguminosae. Vol. 1. Plants and their Constituents (1994), Chapman & Hall, London
2. Cos P., De Bruyne T., Apers S., Vanden Berghe D., Pieters L., and Vlietinck A.J. Phytoestrogens: recent developments. Planta Med. 69 (2003) 589-599
3. Dewick P.M. Isoflavonoids. In: Harborne J.B. (Ed). The Flavonoids. Advances in Research since 1986 (1994), Chapman & Hall, London 117-238
4. Diel P., Smolnikar K., Schulz T., Laudenbach-Leschowski U., Michna H., and Vollmer G. Phytoestrogens and carcinogenesis - differential effects of genistein in experimental models of normal and malignant rat endometrium. Hum. Reprod. 16 (2001) 997-1006
5. El-Masry S., Amer M.E., Abdel-Kader M.S., and Zaatout H.H. Prenylated flavonoids of Erythrina lysistemon grown in Egypt. Phytochemistry 60 (2002) 780-787
6. Krishnan V., Heath H., and Bryant H.U. Mechanism of action of estrogens and selective estrogen receptor modulators. Vitam. Horm. 60 (2000) 123-147
7. Lamartiniere C.A., Zhang X.J., and Cotroneo M.S. Genistein studies in rats: potential for breast cancer prevention and reproductive and developmental toxicity. Am. Clin. Nutr. 68 Suppl. 6 (1998) 1400S-1405S
8. Million Womens Study Collaborators, 2003. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362, 419-427.
9. Njamen D., Talla E., Mbafor J.T., Fomum Z.T., Kamanyi A., Mbanya J.C., Cerdas-Nicolas M., Giner R.M., Recio M.C., and Rios J.L. Anti-inflammatory activity of erycristagallin, a pterocarpene from Erythrina mildbraedii. Eur. J. Pharmacol. 468 (2003) 67-74
10. Njamen D., Mbafor J.T., Fomum Z.T., Kamanyi A., Mbanya J.C., Recio M.C., Giner R.M., Manez S., and Rios J.L. Anti-inflammatory activities of two flavanones, sigmoidin A and sigmoidin B, from Erythrina sigmoidea. Planta Med. 70 (2004) 104-107
11. Nkengfack A.E., Azebaze A.G.B., Waffo A.K., Fomum Z.T., Meyer M., and Van Heerden F.R. Erythrina studies. Part 39. Cytotoxic isoflavones from Erythrina indica. Phytochemistry 58 (2001) 1113-1120
12. Routedge E., and Sumpter J.P. Oestrogenic activity of surfanctants and some of their degradation products assessed using a recombinant yeast screen. Environ. Toxicol. Chem. 15 (1996) 241-248
13. Wiseman H. The bioavaibility of non nutrient plant factors: dietary flavanoids and phytoestrogens. Proc. Nutr. Soc. 58 (1999) 139-146
14. Wober J., Weißwange I., and Vollmer G. Stimulation of alkaline phosphatase activity in Ishikawa cells induced by various phytoestrogens and synthetic estrogens. J. Steroid Biochem. Mol. Biol. 83 (2003) 227-233
15. World Health Organisation. Research on the menopause. Prog. Hum. Reprod. Res. 40 (1996) 1-8
16. Writing Group for the Women′s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized control trial. JAMA 288 (2002) 321-333